Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth annual Drugs to Watch™ report, a trusted guide to the therapies poised to redefine the future of healthcare. This year, the highly anticipated resource highlights 11 drugs projected to achieve blockbuster status or revolutionize treat ...

Core Viewpoint - Clarivate Plc has announced a new share repurchase program of up to $500 million for a two-year period from January 1, 2025, to December 31, 2026, replacing the current program which ends on December 31, 2024 [1][2]. Group 1: Share Repurchase Program - The new share repurchase program will allow the company to buy back its ordinary shares through open-market purchases [1][3]. - The previous share repurchase program resulted in the repurchase of $300 million of ordinary shares, with $200 million repurchased in the third and fourth quarters of 2024 [2]. - The new program reflects the Board's confidence in the company's growth and financial performance, aligning with its Value Creation Plan [3]. Group 2: Financial Management - Clarivate has prepaid $75 million of term-loan debt in the fourth quarter of 2024, totaling $133 million in prepayments for the year [2]. - The company emphasizes a balanced approach to capital allocation, which includes returning capital to shareholders and reducing debt [3]. Group 3: Operational Flexibility - The new share repurchase program does not obligate Clarivate to repurchase a specific dollar amount or number of shares and can be modified or terminated at any time [3]. - The company will conduct open-market purchases based on market conditions, availability of shares, and other factors at management's discretion [3].

Faster and more relevant results to empower critical IP decision-making LONDON, Dec. 12, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of AI Search in Derwent™. Combining artificial intelligence (AI) with the premier source of global patent data, Derwent World Patents Index (DWPI)™, this solution will enable intellectual property (IP) professionals to make reliable innovation decisions by finding more relevant patents in ...

Revealing highly active specialties in sciences and social sciencesLONDON, Nov. 27, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, and the Chinese Academy of Sciences (CAS) today released 2024 Research Fronts™, identifying the most dynamic and rapidly growing specialties in sciences and social sciences. This marks the eleventh annual collaboration between the two organizations, with the report launched at a ceremony held in Beijing today.The report ...

New seven-part series explores disparities in care, funding and innovation impacting half the world's populationLONDON, Nov. 21, 2024 /PRNewswire/ -- BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has launched its new special series, 'Healing the Health Divide.' This seven-part series sheds light on the persistent disparities in women's health research, funding, and treatment.Women make up half of the global population, yet their health remains co ...

Prioritizing research integrity with enhanced filters to address publication and citation manipulation LONDON, Nov. 19, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today revealed its 2024 list of Highly Cited Researchers™ – influential researchers at universities, research institutes and commercial organizations around the world who have demonstrated significant and broad influence in their field(s) of research. Analysts at the Institute for Scie ...

New report analyses Mainland China's transformation into a global biopharma powerhouse, with key insights for international stakeholdersLONDON, Nov. 18, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, in partnership with Healthcare Executive, published by the China Pharmaceutical Enterprises Association, today announced the release of a new report, A Decade of Innovation, A Decade to Come.Over the past decade, Mainland China's biopharmaceutical sector ...

Recognizing Roper St. Francis Healthcare, Bon Secours Mercy Health, and Bronson Methodist Hospital for excellence in Physician and Hospital GroupsLONDON, Nov. 13, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, announced the 2023 winners of the Clarivate Healthcare Business Insights™ annual Revenue Cycle Awards. Now in its 12th year, the Revenue Cycle Awards recognize U.S.-based healthcare organizations for exceptional performance on revenue cycle KPI ...

LONDON, Nov. 12, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has today published its fourth annual sustainability report, showcasing its commitment to sustainability and the United Nations Sustainable Development Goals (SDGs). In 2023, Clarivate was shortlisted for the SDG Pioneer Award at the Thomson Reuters Responsible Business Awards. Newsweek recognized Clarivate as one of "America's Greatest Workplaces for Diversity for 2024" and "America's ...

I recommended a buy rating for Clarivate PLC (NYSE: CLVT ) when I wrote about it on 8 th August, as I believed the upside was attractive given the organic growth recovery story was well I consider an investment ideal if it performs its core business in a sector projected to experience structural (organic) growth in excess of GDP growth over the next 5-10 years; profits from sustainable competitive advantages that translate into attractive unit economics; In the hands of competent, ethical, and long-term thi ...